Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Informa PLC Director's Dealing 2020

Jul 3, 2020

4915_dirs_2020-07-03_72019fb1-707e-41cc-afd0-8a006443a823.html

Director's Dealing

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

National Storage Mechanism | Additional information

RNS Number : 0281S

Informa PLC

03 July 2020

Informa LEI: 5493006VM2LKUPSEDU20

Identification Code: GB00BMJ6DW54

Informa PLC

3 July 2020

Non-Executive Director Shareholding Update

London: Informa PLC ("Informa" or "the Company"), the International Exhibitions, Events, Information Services and Advanced Learning Group, confirms that, in line with the announcement of 26 March 2020, Ordinary Shares were issued to the Chairman and Non-Executive Directors on 2 July in lieu of their net fees for June 2020:

PDMR Ordinary Shares
David Flaschen 739
Derek Mapp 2,768
Gareth Bullock 554
Gill Whitehead 1,177
Helen Owers 507
John Rishton 490
Mary McDowell 694
Stephen Davidson 465
Total 7,394

These shares were issued at £4.704 per share, being the closing share price on 30 June 2020.

Enquiries
Informa PLC

Heledd Hanscomb, Deputy Company Secretary
+44 (0)20 7017 5000

Informa PLC

Informa is a leading international Exhibitions, Events, Information Services and Scholarly Publishing Group. It helps commercial, professional and academic communities work smarter and make better decisions faster, through specialist content and intelligence, and opportunities to connect and learn. For more information, please visit www.informa.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHKZGGNZFRGGZM